Use of recombinant activated factor VII (Novoseven) in trauma and surgery: analysis of outcomes reported to an international registry
Grounds RM, Seebach C, Knothe C, Paluszkiewicz P, Smith TS, Kasal E, Lecumberri R [ES], Urbanec R, Haas T, Wujtewicz M, Rehorkova D, Pelichovska M, Lange M, Uranga M, Bosman R, Rommes JH, Koscielny J.
Anaesthesia and Intensive Care Medicine, St George's Hospital, Tooting, London, UK
Revisão:Journal of Intensive Care Medicine
Data: 1/Fev/2006Hematologia e Hemoterapia
The objective was to evaluate the efficacy and safety of recombinant activated factor VII in patients with massive bleeding.
Forty-five patients with severe massive hemorrhage requiring>or= 14 transfusion units of packed red blood cells received recombinant activated factor VII. Postdrug blood loss and transfusion requirements were assessed, and mortality was compared with predicted outcomes.
Blood loss was markedly reduced in 40 of 43 (93.0%) patients, and transfusion requirements decreased after recombinant activated factor VII administration. Mortality rate in trauma patients who had massive hemorrhage was significantly reduced compared with predictions using scoring systems. This may be associated with the use of recombinant activated factor VII.
This study failed to demonstrate an improvement in surgical patients. The absence of concurrent controls prevents definitive conclusions regarding actual safety or efficacy of recombinant activated factor VII.
CITAÇÃO DO ARTIGO J Intensive Care Med. 2006 Jan-Feb;21(1):27-39
A Clínica é o hospital privado com maiores recursos tecnológicos de Espanha, tudo num único centro.
Os profissionais da Clínica realizam um trabalho contínuo de investigação e formação, sempre em benefício do paciente.
Conheça porque é que somos diferentes em relação a outros centros sanitários. Qualidade, rapidez, comodidade e resultados.